Latest "Placebo Hepatitis Virus Infection" News Stories

16:14 EST 1st February 2015 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 10,000+

Extremely Relevant

[Comment] Hepatitis virus and HIV interactions

Because of shared routes of transmission, 5–25% of the 34 million people with HIV worldwide are co-infected with either hepatitis B virus (HBV), hepatitis C virus (HCV), or both, with the highest number of co-infections in low-income countries. The...

[Articles] HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–12: a retrospective observational cohort study

Screening for viral hepatitis is important in individuals diagnosed as HIV positive. Effective management for viral hepatitis should be integrated into HIV treatment programmes. Long-term data are needed about the effect of hepatitis co-infection on ...

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients af...

Should Direct-Acting Antiviral Agents Replace the Standard of Care for Hepatitis C Infection?

Lansdale, PA (PRWEB) September 15, 2014 For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administr...

Genes show the way to better treatment of hepatitis A

One of the most common causes of hepatitis A (formerly known as infectious hepatitis) is a hepatitis C virus infection in the liver. The disease can be treated medically, but not all patients are cured by the treatment currently available. New resear...

Genes show the way to better treatment of hepatitis C

(Aarhus University) One of the most common causes of hepatitis C (formerly known as infectious hepatitis) is a hepatitis C virus infection in the liver. The disease can be treated medically, but not all patients are cured by the treatment currently a...

Life expectancy among patients with chronic hepatitis C virus infection and cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced su...

Viekirax and Exviera for the Treatment of Chronic Hepatitis C Virus Infection

Viekirax (ombitasvir / paritaprevir / ritonavir) and Exviera (dasabuvir) is indicated for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection and compensated cirrhosis.

Researchers discover how Hepatitis C virus persists for years

Hepatitis C virus (HCV) lingers in the human body for years, slowly damaging the liver and leading to liver diseases such as hepatitis, cirrhosis and liver cancer, which is often fatal. Research conducted at the University of North Carolina at Chapel...

BMS awards nine new grants to fight against hepatitis B and C in China and India

The Bristol-Myers Squibb Foundation has announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vuln...

Medical News Today: Study identifies global prevalence of hepatitis C virus genotypes

Researchers from the UK have identified the worldwide prevalence of hepatitis C virus genotypes, in the hope it will help develop new treatment strategies for the infection.

Latest advances in hepatitis C therapy

The availability of new protease inhibitors is revolutionising the treatment of hepatitis C virus infection.

Widespread hepatitis C screening may result in more harms than benefits

Several organizations have recommended scaling up screening for hepatitis C infection. But experts warn that no study has tested whether this will lead to net clinical benefit or harm. Hepatitis C is a virus that can infect and damage the liver.

Hepatitis A hospitalization rate declines in U.S.

The rate of hospitalization due to hepatitis A virus (HAV) infection has significantly declined in the U.S. from 2002 to 2011, new research shows. Findings show that older patients and those with chronic liver disease are most likely to be hospitaliz...

Enanta reports results from TURQUOISE-I study in chronic hepatitis C patients with HIV-1 co-infection

Enanta Pharmaceuticals, a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced at The Liver Meeting 2014 results from studies in chronic hepatitis C virus (HCV) p...

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to mai...

Hepatitis A hospitalization rate declines in US

(Wiley) New research reports that the rate of hospitalization due to hepatitis A virus infection has significantly declined in the US from 2002 to 2011. Findings published in Hepatology, a journal of the American Association for the Study of Liver Di...

GlobalData Analyst: Harvoni Will Keep Gilead Atop Hepatitis C Virus Treatment Landscape

The recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company ...

Bristol-Myers Squibb Foundation awards nine grants to support care for high-risk patients with hepatitis B and C in China and India

The Bristol-Myers Squibb Foundation today announced nine new grants totaling more than $3.5 million to strengthen efforts in China and India in the fight against hepatitis B virus (HBV) and hepatitis C virus (HCV) infection by focusing on the most vu...

Well-Controlled Hepatitis C No Dent on Lifespan

Survival in patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who achieved sustained virological response is similar to that of the general population. Medscape Medical News

FDA approves first combination pill to treat hepatitis C

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

[Articles] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTH

Once-daily grazoprevir plus elbasvir with or without ribavirin for 12 weeks in previously untreated HCV-mono-infected and HIV/HCV-co-infected patients without cirrhosis achieved SVR12 rates of 87–98%. These results support the ongoing phase 3 devel...

Hepatitis C ruled out as cause of mental impairment in HIV patients

(Washington University School of Medicine) Infection with the hepatitis C virus does not contribute to the problems in mental functions seen in many patients with long-term HIV infections, a new study reveals.

Harvoni (ledipasvir/sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1 Infection

Developed by Gilead Sciences, Harvoni (ledipasvir/sofosbuvir) is the first combination pill approved for the treatment of adult patients with chronic hepatitis C genotype 1 infection.

Peginterferon lambda-1a for hepatitis C

Peginterferon lambda-1a is intended for the treatment of hepatitis C virus (HCV) infection in adult patients who are treatment naïve or have relapsed to prior pegylated alfa interferon, including patients with compensated cirrhosis without evidence of portal hypertension, and in patients with HIV co-infection. If licensed, peginterferon lambda-1a would offer an additional treatment option for pat...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks